Apple Faces Regulatory Heat For Procuring iPhone 14 Chips From Controversial Chinese Chipmaker

Republican lawmakers warned Apple Inc (NASDAQ:AAPL) against intense scrutiny lest it procured memory chips from controversial Chinese semiconductor manufacturer Yangtze…
  • Republican lawmakers warned Apple Inc (NASDAQ:AAPL) against intense scrutiny lest it procured memory chips from controversial Chinese semiconductor manufacturer Yangtze Memory Technologies Co for the new iPhone 14, the Financial Times reports.
  • The lawmakers expressed alarm at reports suggesting Apple would add the Yangtze to its list of suppliers for Nand flash memory chips meant for storing data on smartphones.
  • Apple acknowledged not using YMTC chips in products and evaluated sourcing from YMTC for Nand chips for some iPhones sold in China.
  • The lawmakers argued that YMTC has extensive ties to the Chinese Communist party and military and broke export control laws by selling goods to Huawei Technologies Co, Ltd. 
  • Apple will effectively be transferring knowledge and know-how to YMTC that will supercharge its capabilities and help the CCP achieve its national goals, they cautioned.
  • A Democratic lawmaker has also privately raised concerns about YMTC.
  • Earlier, a bipartisan group of senators urged the government to put YMTC on the “entity list” for violating export control rules by selling memory chips to Huawei. 
  • They accused Beijing of subsidizing YMTC, making way for it to dominate the sector.
  • Apple did not respond to lawmakers’ and congressional YMTC-related speculation queries. 
  • Recently U.S. restricted sales of high-performance AI Nvidia Corp (NASDAQ: NVDA) chips for servers, the A100 and H100, to China and Russia. 
  • Price Action: AAPL shares traded higher by 0.67% at $155.49 in the premarket on the last check Friday.
  • Photo by Matias Cruz from Pixabay
Total
0
Shares
Related Posts
Read More

Adverum Biotechnologies Presented Nonclinical Data Sunday at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced nonclinical data supporting the two doses of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) being evaluated in the Phase 2 LUNA trial and the potential for staggered, bilateral administration in the treatment of wet AMD.

ADVM